Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV‐infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks
- 25 January 2005
- journal article
- clinical trial
- Published by Wiley in HIV Medicine
- Vol. 6 (1), 13-20
- https://doi.org/10.1111/j.1468-1293.2005.00259.x
Abstract
To evaluate the long-term safety and efficacy of the combination of hydroxychloroquine, hydroxyurea and didanosine. We recruited antiretroviral-naive patients with viral loads less than 100 000 HIV-1 RNA copies/mL and CD4 counts greater than 150 cells/microL. All patients received hydroxychloroquine (200 mg), hydroxyurea (500 mg) and didanosine (125-200 mg) twice daily. Clinical and laboratory safety assessments and measurements of viral load and CD4 count were made at regular intervals, and genotypic resistance testing was performed on samples with detectable viral load at 48, 96 and 144 weeks. Fourteen of the 17 patients who commenced therapy remained on treatment at 144 weeks. Treatment was well tolerated but caused neutropenia, usually mild and transient, in 12 patients (71%). Mean viral load was reduced by 1.6 log(10) copies/mL below baseline (P<0.001), eight patients (47%) had undetectable viral load (<400 copies/mL), and two patients (12%) had detectable viral load but no detectable resistance mutations at week 144. Four patients (24%) had detectable viral load together with major resistance mutations (three with both 74 V and 184 V, and one with both 62 V and 65R) at week 144, but still had viral load suppression below baseline. Mean CD4 count was increased by 106 cells/microL above baseline (P=0.07) at week 144. This novel and well-tolerated combination controls viral replication during long-term follow up, with development of few resistance mutations. With careful monitoring it may be a useful strategy for delaying highly active antiretroviral therapy (HAART) and associated toxicity in selected patients with low initial viral loads.Keywords
This publication has 23 references indexed in Scilit:
- Diminished RNA Primer Usage Associated with the L74V and M184V Mutations in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 Provides a Possible Mechanism for Diminished Viral Replication CapacityJournal of Virology, 2003
- Molecular Mechanisms of Resistance to Human Immunodeficiency Virus Type 1 with Reverse Transcriptase Mutations K65R and K65R+M184V and Their Effects on Enzyme Function and Viral Replication CapacityAntimicrobial Agents and Chemotherapy, 2002
- Long-Term Safety and Antiretroviral Activity of Hydroxyurea and Didanosine in HIV-Infected PatientsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
- Long-term hydroxyurea in combination with didanosine and stavudine for the treatment of HIV-1 infectionAIDS, 2000
- A Randomized Study of the Safety and Antiretroviral Activity of Hydroxyurea Combined with Didanosine in Persons Infected with Human Immunodeficiency Virus Type 1The Journal of Infectious Diseases, 2000
- Chloroquine Exerts an Additive in Vitro Anti-HIV Type 1 Effect When Associated with Didanosine and HydroxyureaAIDS Research and Human Retroviruses, 1999
- Inhibition of HIV-1 replication by hydroxychloroquine: mechanism of action and comparison with zidovudineClinical Therapeutics, 1996
- Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1Clinical Therapeutics, 1995
- Inhibition of Human Immunodeficiency Virus Type 1 Replication by Hydroxychloroquine in T Cells and MonocytesAIDS Research and Human Retroviruses, 1993
- Inhibition of Human Immunodeficiency Virus Infectivity by ChloroquineAIDS Research and Human Retroviruses, 1990